Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Advanced Therapy Medicinal Products CDMO Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
5.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Product Market Map
5.3.1. By Product
5.3.2. By Phase
5.3.3. By Indication
5.3.4. By Region
6. North America Advanced Therapy Medicinal Products CDMO Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
6.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
6.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others)
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Advanced Therapy Medicinal Products CDMO Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Phase
6.3.1.2.3. By Indication
6.3.2. Canada Advanced Therapy Medicinal Products CDMO Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Phase
6.3.2.2.3. By Indication
6.3.3. Mexico Advanced Therapy Medicinal Products CDMO Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Phase
6.3.3.2.3. By Indication
7. Europe Advanced Therapy Medicinal Products CDMO Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
7.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
7.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others)
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Phase
7.3.1.2.3. By Indication
7.3.2. United Kingdom Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Phase
7.3.2.2.3. By Indication
7.3.3. France Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Phase
7.3.3.2.3. By Indication
7.3.4. Italy Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Phase
7.3.4.2.3. By Indication
7.3.5. Spain Advanced Therapy Medicinal Products CDMO Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Phase
7.3.5.2.3. By Indication
8. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
8.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
8.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others)
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Phase
8.3.1.2.3. By Indication
8.3.2. Japan Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Phase
8.3.2.2.3. By Indication
8.3.3. India Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Phase
8.3.3.2.3. By Indication
8.3.4. Australia Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Phase
8.3.4.2.3. By Indication
8.3.5. South Korea Advanced Therapy Medicinal Products CDMO Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Phase
8.3.5.2.3. By Indication
9. South America Advanced Therapy Medicinal Products CDMO Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
9.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
9.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others)
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Advanced Therapy Medicinal Products CDMO Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Phase
9.3.1.2.3. By Indication
9.3.2. Argentina Advanced Therapy Medicinal Products CDMO Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Phase
9.3.2.2.3. By Indication
9.3.3. Colombia Advanced Therapy Medicinal Products CDMO Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Phase
9.3.3.2.3. By Indication
10. Middle East and Africa Advanced Therapy Medicinal Products CDMO Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
10.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
10.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others)
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Advanced Therapy Medicinal Products CDMO Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Phase
10.3.1.2.3. By Indication
10.3.2. Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Phase
10.3.2.2.3. By Indication
10.3.3. UAE Advanced Therapy Medicinal Products CDMO Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Phase
10.3.3.2.3. By Indication
10.3.4. Kuwait Advanced Therapy Medicinal Products CDMO Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Product
10.3.4.2.2. By Phase
10.3.4.2.3. By Indication
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
14.6.1. Celonic AG
14.6.2. Bio Elpida
14.6.3. Rentschler Biopharma SE
14.6.4. AGC Biologics GmbH
14.6.5. Catalent Inc
14.6.6. Lonza Group AG
14.6.7. WuXi Advanced Therapies
14.6.8. Minaris Regenerative Medicine
14.6.9. Patheon Inc
14.6.10. Cell and Gene Therapy Catapult
15. Strategic Recommendations
16. About Us & Disclaimer